Dabrafenib (Tafinlar) CAS 1195765-45-7 for Skin Cancer GSK2118436 from China manufacturer

Dabrafenib (Tafinlar) CAS 1195765-45-7 for Skin Cancer GSK2118436

Price:	1.0 USD
Payment Terms:	T/T,WU,Money Gram;Bitcoin
Place of Origin:	Guangdong, China (Mainland)


	Add to My Favorites
HiSupplier Escrow	Share \|

Product Detail

Means of Transport: Ocean,Land,Air

Packing: 25kg/Drum

Production Capacity: 1000kg/month

Delivery Date: 4days

CAS NO: 1195765-45-7
MF: C23H20F3N5O2S2
MW: 519.5624096
EINECS: 200-366-3
Appearance: White to slightly yellowish-white crystalline
Assay: 99%min

Dabrafenib Profile

Product name: Dabrafenib

Synonyms: Dabrafenib;N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;Dabrafenib free base(GSK2118436A);Dabrafenib(GSK2118436);GSK2118436A;Dabrafenib (GSK2118436);Dabrafenib KB-57246;Debrafenib API

CAS NO: 1195765-45-7

MF: C23H20F3N5O2S2

MW: 519.5624096

EINECS: 200-366-3

Appearance: White to slightly yellowish-white crystalline

Assay: 99%min

Storage: Shading, confined preservation

Dabrafenib Description

Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.

The Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600Emutation-positive advanced melanoma on May 30, 2013.Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months.To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib.On January 8, 2014, the FDA approved this combination of dabrafenib and trametinib for BRAF V600E/K-mutant metastatic melanoma.

Dabrafenib Application

Dabrafenib is used to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.